Content about C1-inhibitor

December 27, 2013

Drug maker Shire is extending the deadline for its offer to buy Exton, Pa.-based ViroPharma for $4.2 billion, Shire said Friday.

DUBLIN — Drug maker Shire is extending the deadline for its offer to buy Exton, Pa.-based ViroPharma for $4.2 billion, Shire said Friday.

The company said it had extended the expiration date of its tender offer for ViroPharma until Jan. 9. The offer had previously been planned to expire on Thursday. Shire announced the $50-per-share offer last month.

December 12, 2012

Drug maker ViroPharma has launched an education campaign focused on a rare, debilitating and life-threatening genetic disorder.

EXTON, Pa. — Drug maker ViroPharma has launched an education campaign focused on a rare, debilitating and life-threatening genetic disorder.

The company announced Wednesday the launch of the unbranded campaign focused on hereditary angioedema, particularly the emotional and psychological burden faced by patients with the disease, which results from deficiency of the human plasma protein C1 inhibitor and causes attacks of swelling and pain.

August 26, 2011

The Food and Drug Administration has approved a drug made by Shire for a rare autoimmune condition, the agency said.

SILVER SPRING, Md. — The Food and Drug Administration has approved a drug made by Shire for a rare autoimmune condition, the agency said.

The FDA announced the approval of Firazyr (icatibant) for acute attacks of hereditary angioedema in patients ages 18 years and older. HAE, which affects fewer than 30,000 people in the United States, results from improper function of C1 inhibitor, a protein that regulates how certain immune system and blood clotting pathways function.

December 3, 2010

The Specialty Pharmacy Nursing Network has entered a partnership with ViroPharma’s CinryzeSolutions support program, a training and monitoring program for patients using ViroPharma’s Cinryze (C1 esterase inhibitor [human]) who wish to administer the drug themselves.

SARASOTA, Fla. — The Specialty Pharmacy Nursing Network has entered a partnership with ViroPharma’s CinryzeSolutions support program, a training and monitoring program for patients using ViroPharma’s Cinryze (C1 esterase inhibitor [human]) who wish to administer the drug themselves.

Cinryze is a drug administered via infusion for the treatment of hereditary angioedema, and the partnership will allow patients to receive training and follow-up support from SPNN nurses, as well as direction from their physicians.